Orthocell to Brief Investors on US Rollout of Remplir and Operational Progress

Orthocell Ltd ( (AU:OCC) ) has provided an announcement.

Orthocell Limited will host an investor webinar on 2 February 2026 to provide an operational update, with a particular focus on the rollout of its Remplir nerve repair device in the United States. The briefing, led by the company’s chairman and chief executive, underscores the strategic importance of the US market to Orthocell’s growth, following recent regulatory clearances and the establishment of a specialist US distributor network that has already generated initial sales, and will give investors and stakeholders further insight into how its expanding product portfolio and regulatory progress are shaping its commercial trajectory in regenerative medicine.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

More about Orthocell Ltd

Orthocell Limited is a Perth-based regenerative medicine company focused on restoring mobility by developing products for the repair of bone and soft tissue injuries. Its portfolio includes collagen-based medical devices such as Striate+ for dental guided bone regeneration, which is cleared in key markets including the US, Europe and Brazil and distributed globally via BioHorizons, as well as Remplir, a peripheral nerve repair device approved in the US, Australia, New Zealand, Singapore, Thailand, Canada and Hong Kong. The company is also advancing SmrtGraft for tendon repair under special access and clinical trial pathways in Australia, and is progressing autologous cell therapies targeting tendon and cartilage regeneration, with an emphasis on US market entry through technology transfer and regulatory engagement.

Average Trading Volume: 547,308

Technical Sentiment Signal: Hold

Current Market Cap: A$263.2M

See more data about OCC stock on TipRanks’ Stock Analysis page.